Table 1.
Characteristic of case-control studies of hepatitis B virus infection and intrahepatic cholangiocarcinoma risk
| Study | Study design | Dates | Cases |
Controls |
Source | OR (95%CI) for HBV infection (serum HBsAg, unless stated otherwise) | ||
| Total | With exposure | Total | With exposure | |||||
| Donato et al[24], 2001 | Case-control | 1995-2000 | 26 | 13% | 824 | 5.5% | Hospital | 2.7 (0.4-18.5) |
| Yamamoto et al[15], 2004 | Case-control | 1991-2002 | 50 | 4% | 205 | 2% | Hospital | 1.84 (0.34-10.11) |
| Shaib et al[11], 2005 | Case-control | 1993-1999 | 625 | 0.2% | 90834 | 0.2% | Population | 0.8 (0.1-5.9) |
| Choi et al[30], 2006 | Case-control | 2003-2004 | 51 | 7.8% | 51 | 9.8% | Hospital | 0.8 (0.2-3.02) |
| Shaib et al[12], 2007 | Case-control | 1992-2002 | 83 | 1.2% | 236 | 0.4% | Hospital | 2.9 (0.1-236.8) |
| anti-HBc | ||||||||
| 28.6 (3.9-1268.1) | ||||||||
| Lee et al[19],2008 | Case-control | 2000-2004 | 622 | 13.5% | 2488 | 5.0% | Hospital | 2.3 (1.6-3.3) |
| Zhou et al[22], 2008 | Case-control | 2004-2006 | 312 | 48.4% | 438 | 9.6% | Hospital | 8.9 (5.97-13.19) |
| Tao et al[20], 2009 | Case-control | 1998-2008 | 61 | 27.9% | 380 | 5.0% | Hospital | 7.3 (3.1-17.2) |
| Lee et al[28],2009 | Case-control | 1991-2005 | 160 | 37.5% | 160 | 13.8% | Hospital | 4.99 (2.78-8.95) |
| Tanaka et al[23], 2010 | Cohort | 1991-1993 | 9.08%1 | 0.66%2 | 7.6 yr of follow-up | 8.56 (1.33-55.20) | ||
| Zhou et al[21], 2010 | Case-control | 2003-2006 | 317 | 48.6% | 634 | 6.6% | Hospital | 9.67 (6.33-14.77) |
| Peng et al[26], 2011 | Case-control | 2002-2009 | 98 | 31.6% | 196 | 12.8% | Hospital | 2.75 (1.27-5.95) |
| Fwu et al[29], 2011 | Cohort | 1983-2000 | 0.43%3 | 0.09%4 | 6.91 yr of follow-up | 4.80 (1.88-12.20) | ||
| Welzel et al[13], 2011 United States | Case-control | 1993-2005 | 743 | 1.5% | 195953 | 0.2% | Population | 3.1 (1.43-6.58) |
| Chaiteerakij et al[27], 2013 | Case-control | 2000-2010 | 612 | 3.0% | 594 | 3.0% | Hospital | |
1
Incidence rate of intrahepatic cholangiocarcinoma (ICC) per 100000 hepatitis B surface antigen (HBsAg)-seropositive person-years;
2
Incidence rate of ICC per 100000 HBsAg and anti-hepatitis C virus-seronegative person-years;
3
Incidence rate of ICC per 100000 HBsAg-seropositive woman-years;
4
Incidence rate of ICC per 100000 HBsAg-seronegative woman-years. HBV: Hepatitis B virus; Anti-HBc: Hepatitis B core antibody.